Gene-directed enzyme prodrug therapy (GDEPT) is a promising and emerging strategy that attempts to limit the systemic toxicity inherent to cancer chemotherapy by means of tumor-targeted delivery and expression of an exogenous gene whose product converts nontoxic prodrug(s) into activated cytotoxic agent(s). The bacterial nitroreductase (NTR) enzyme, coupled with its substrate prodrug 5-(azaridin-1-yl)-2,4-dinitrobenzamide (CB1954), is a promising GDEPT strategy that has reached clinical trials. However, no strategy exists to visually monitor and quantitatively evaluate the therapeutic efficacy of NTR/CB1954 prodrug therapy in cells and imaging in living animals. As the success of any GDEPT is dependent upon the efficiency of transgene expression in vivo, we developed a safe, sensitive and reproducible noninvasive imaging method to monitor NTR transgene expression that would allow quantitative assessment of both therapeutic efficacy and diagnostic outcome of NTR/ CB1954 prodrug therapy in the future. Here, we investigate the use of a novel fluorescent imaging dye CytoCy5S (a Cy5-labeled quenched substrate of NTR enzyme) on various cancer cell lines in vitro and in NTR-transfected tumor-bearing animals in vivo. CytoCy5S-labeled cells become fluorescent at 'red-shifted' wavelengths (638 nm) when reduced by cellular NTR enzyme and remains trapped within the cells for extended periods of time. The conversion and entrapment was dynamically recorded using a time-lapsed microscopy. Systemic and intratumoral delivery of CytoCy5S to NTR-expressing tumors in animals indicated steady and reproducible signals even 16 h after delivery (Po0.001). This is the first study to address visual monitoring and quantitative evaluation of NTR activity in small animals using CytoCy5S, and establishes the capability of NTR to function as an imageable reporter gene.
INTRODUCTION
High systemic toxicity remains a serious side effect and the cause of dose-limiting constraint of conventional chemotherapy. To minimize unwanted toxicity to noncancerous cells, and to maximize the concentration of chemotherapeutic drugs to tumors, various targeted therapies are being developed. Gene-directed enzyme prodrug therapy (GDEPT) is a promising strategy that addresses the limitations of conventional chemotherapy. GDEPT is a suicide gene therapy based anticancer strategy that relies on selective introduction and expression of foreign gene(s) into tumor cells, followed by gene productmediated activation of inert prodrugs into cytotoxic agents, resulting in localized tumor cell death and providing therapeutic selectivity. 1 Prodrug activation within gene-modified cancer cells generates (1) toxic levels of drug concentrations limited only to tumor cells, (2) minimum toxicity to normal cells and (3) higher therapeutic index during cancer therapy. Apart from that, due to limitation of transfection efficiency, usually only a small number of cancer cells within a tumor can express the foreign genes. The active prodrug can not only kill the tumor cells, but also create a zone of dead cells around the cancer cells modified to express transgenes through bystander effect. 2 For the success of GDEPT in a clinical setting, it is essential to be able to monitor the transgene expression and function in vivo. Optimization of gene transfer protocols, vector development and prodrug dosing schedules are some of the key criteria essential for translation of a GDEPT candidate to human applications. There is a growing awareness that assessment of location, magnitude and duration of transgene expression in vivo through various modern noninvasive imaging technologies may help develop efficient and safe gene therapy protocols. 3, 4 Currently, the three most promising suicide gene/prodrug combinations are (1) herpes simplex virus thymidine kinase (HSV1-tk) with ganciclovir (GCV), 5 (2) CD (cytosine deaminase) from bacteria or yeast with 5-fluorocytidine 6,7 and (3) bacterial nitroreductase (NTR) with CB1954. 8 Of the three, HSV1-tk/GCV is at the forefront of gene therapy. 9, 10 The advancement and success of HSV1-tk gene therapy in clinics is due to its dual capability to act as a therapeutic gene as well as a reporter gene that can be imaged by appropriate radioactive probe under PET/SPECT (positron emission tomography/single photon emission computed tomography) scanners. 11 Such dual functionality has enormous impact on acquiring information about the extent of gene expression, vector dose, tumor selectivity and biodistribution, and can help monitor the impact of prodrug therapy. [12] [13] [14] In the last decade, a number of promising reporter genes with compatible imageable probes were developed for small animal imaging. 15, 16 Tools and techniques were developed for imaging live animals under small animal optical scanners, utilizing various bioluminescent optical reporter genes such as Firefly and Renilla luciferase 17 and fluorescent reporters like GFP and RFP. 18 In nuclear imaging, both PET and SPECT reporter proteins with compatible substrates tagged with radioisotopes are now available. 19 Several radiotracers, including, 11 Carbon 18 Fluorine, 124 Iodine, 64 Copper and 68 Gallium, are used to label enzyme substrates for PET imaging, whereas 123 Iodine, 131 Iodine, 111 Indium and 99 Technetium are used for SPECT imaging. 20 However, currently there are very few therapeutic reporters for suicide gene therapy that contain a direct imageable probe and whose resultant image from probe-enzyme interaction brings information about probe localization or tracks expression of the transgene in vivo.
In the present investigation, we explore whether NTR, a wellstudied GDEPT gene, has the potential to act as a reporter gene similar to HSV1-tk. We utilize a novel substrate (CytoCy5S) as a probe to image NTR gene-expressing tumors in live animal, using optical small animal scanners. This study demonstrates for the first time that various tumor models stably expressing NTR reporter gene can be imaged noninvasively, quantitatively and repetitively without loss of signal, making it a promising strategy for future therapeutic evaluation of NTR in preclinical and clinical settings.
RESULTS

Evaluation of Escherichia coli NTR enzyme expressed in mammalian cells by quenched fluorescent substrate CytoCy5S
The bacterial Nitroreductase gene (nfnB, renamed NTR2 here) was cloned from E. coli (K12) strain, in a mammalian expression vector under a constitutive cytomegalovirus promoter (Figure 1a) . The sequence-confirmed NTR construct showed a single amino acid difference (R107H) from the E. coli NTR cDNA (nfnB, Gene bank accession number: U07860) used previously by others. The functional efficiency of expressed NTR gene was evaluated in several transient and stably transfected mammalian cell lines (LS174T, SKOV3, MCF7 and 293T) using various optical fluorescent scanners such as Incell Analyzer 1000 (GE Healthcare, Piscataway, NJ, USA), Nikon Eclipse TE2000-U fluorescent microscope (Nikon, Melville, NY, USA) and fluorescent cell sorter (BD Biosciences, San Jose, CA, USA) analysis. The cell-permeable pro-fluorogenic quenched substrate CytoCy5S was used for the assay. CytoCy5S is a membrane-permeable quenched substrate that is reduced to its fluorescent form by NTR enzyme and the fluorescent product is retained within the cell for prolonged period of time, thereby making it a viable live cell-imaging agent (Figure 1b) . The substrate CytoCy5S produced Cy5-fluorescent signal only from cells transfected to express NTR enzyme, as shown in the panel of cell lines in Figure 1c . Quantitative evaluation of fluorescent signal in stably transfected 293T cells after exposure to 100 ng ml -1 CytoCy5S for 60 min showed a log-order elevation in fluorescent signal compared with corresponding control cells (Figure 1d) . Similarly, to test intracellular Cy5 signal with the expressed message, 293T cells transfected with different concentration of plasmid expressing NTR was analyzed by fluorescence activated cell sorter (FACS), 60 min after exposure to 100 ng ml -1 of substrate CytoCy5S. The results found plasmid concentration-dependent increase in the cellular fluorescent signal (Supplementary Figure 1) . Noninvasive optical imaging of NTR GDEPT system S Bhaumik et al detectable signals from the control tumor sites. We also imaged three additional animals bearing 293T-NTR tumor xenografts in their flank, by intravenous injection of substrate CytoCy5S (Supplementary Figure 2) . The animals imaged 1, 3 and 5 days after substrate injection showed significantly (Po0.01) higher amount of signal on day 1, and it gradually dropped over time (days 3 and 5) but retained 450% of its initial signal on day 5. The same group of animals was re-injected with substrate CytoCy5S after imaging on day 5, and imaged again on days 1, 3 and 5 after second substrate injection. As the signal from the previous substrate injection stays for a prolonged period of time, we were not able to measure the exact amount of signal from the second injection. However, the dropped signal increased significantly when we re-injected the second dose of substrate and the results correlated with tumor size (P¼0.0067, R 2 ¼0.87; Supplementary Figure 2) . In addition, we also imaged another group of three animals bearing 293T and 293T-NTR tumor xenografts in their flank following intravenous injection of substrate CytoCy5S. The tumor size and the fluorescent signals were measured 24 h after substrate injection (Supplementary Figure 3) . We found a positive correlation between the tumor size and the fluorescent signal in these tumors. Imaging NTR enzyme expressed by the gut microbial population in living animals NTR is a protein normally expressed in E. coli and some other microbial species. To monitor the CytoCy5S substrate redution by the microbial populations present in digestive tract of mice, the animals were imaged after injecting CytoCy5S. The animals imaged after intravenous and intraperitoneal injections of 50 mg of CytoCy5S substrate by IVIS-100 Imaging System and eXplore Optix Imaging systems showed significant amounts of fluorescent signals from the abdominal area (Figures 6a-d) . When the animals were pretreated with antibiotic doxycycline for 48 h before imaging to reduce microbial populations in the digestive system, a significant reduction in the level of fluorescent signals (15±5-fold, P¼0.002) was recorded in the peritoneal region (Figures 6b and c) .
DISCUSSION
GDEPT is an emerging strategy involving tumor-targeted delivery of an exogenous gene that expresses an enzyme capable of converting a nontoxic prodrug into an activated cytotoxic agent. 21 The primary aim of this study design is to enhance therapeutic selectivity of chemotherapeutic drugs toward cancerous cells without affecting the surrounding noncancerous normal tissues. However, because the therapeutic efficacy of this procedure is dependent on the level of transgene expression in vivo, it is important to monitor the expression of the exogenous gene using a safe, repetitive and noninvasive method. One of the successful GDEPT strategies currently in clinical trials is a combination of herpes simplex thymidine kinase and prodrug GCV (HSV1-tk-GCV) whose active metabolites inhibit DNA synthesis and kill mainly proliferating cells. The use of HSV1-tk as a reporter gene in combination with various radiotracer-based imaging is one of the keys to the success to this therapy. 19, 22 NTR/CB1954 is another GDEPT strategy with therapeutic potential that is currently in clinical trials. 8 The NTR enzyme is responsible for reduction of nontoxic prodrug CB1954 to its activated cytotoxic form (5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide: a DNA inter-strand cross-linking agent) that kills cancer cells expressing the enzyme. In contrast to the HSV1-tk/GCV strategy, NTR/CB1954 is expected to demonstrate superior therapeutic efficacy, as it kills both dividing and growth-arrested cancer cells, exhibits potent bystander effect and lacks resistance to common chemotherapeutic agents such as cisplatin. 2 As NTR does not naturally express in eukaryotes, a significant advantage of this system is tumor-restricted delivery, therapy and detection without background interference. The success of HSV1-tk is the substrate GCV can perform as prodrug for treatment, and its radiolabeled version can serve as probe PET imaging. TK-based PET imaging can be used from small animals to large animals including human. Whereas in NTR system, CB1954 is used as a prodrug, and CytoCy5S, an entirely new substrate, is used as fluorescence imaging probe with a limited small animal imaging capability.
In this present investigation, we explore the potential of NTR gene as a reporter gene that could have a significant impact on GDEPT. 23 Clinical trials with NTR/CB1954 started in late 1990s when pharmacokinetics of CB1954 was tested in a phase I study on patients with primary and secondary liver tumors. 24 More recently, a replication-defective adenoviral vector CTL102 encoding gene has been used on patients with primary or secondary liver cancer 25 and prostate cancer. 8, 26 However, there are many challenges yet to be overcome for it to be considered a robust therapy. For any GDEPT system, there is a need for methods to monitor sufficient incorporation of the transgenes into tumor cells, gauge adequate level of gene expression and predict the duration of transgene expression in cancer Noninvasive optical imaging of NTR GDEPT system S Bhaumik et al cells. It is becoming increasingly clear that for the success of GDEPT therapy, simultaneous advancement in vector technology, delivery mechanism and compatible imaging techniques are essential to provide in vivo assessment of gene expression, which in turn would facilitate the development of clinical applications of the therapy. 27 The current study aimed to develop a sensitive and reproducible noninvasive imaging method for mapping NTR gene expression in vivo by noninvasive optical imaging in tumor-bearing mice. Although NTR/CB1954 is a well-known GDEPT combination, new treatment agents are continually being designed to improve the therapy efficacy. 28, 29 It is imperative that potential new drugs and diagnostic agents be thoroughly evaluated on small animals at preclinical stages before translation into clinical settings. Therefore, it is important to develop safe, sensitive and reproducible noninvasive imaging methods that can provide repetitive assessment of biodistribution, therapeutic efficacy and diagnostic outcome of the agent(s) during preclinical studies. The optical probe CytoCy5S used in this study becomes fluorescent when reduced by cellular NTR enzyme and remains trapped within cells for extended periods of time, thereby enabling serial and repetitive noninvasive imaging for the live subject. Our study was successful in developing an imaging strategy for monitoring NTR gene expression by novel noninvasive imaging of CytoCy5S. It should be noted that, as CytoCy5 is an optical probe, the fluorescence-based imaging method will be limited to preclinical application. However, radionuclide labeling of CytoCy5S may have potential for translation to clinics.
CytoCy5S is a promising imaging agent for NTR gene expression in vitro and is used in various high content cell analysis. 30 The novel quenched cyanine fluor analog is designed to be nontoxic and cellpermeable, capable of localizing within the cytosol and generating minimal background signal from cells in the absence of NTR enzyme. However, once inside a cell that expresses NTR enzyme, the nitro-group of the dye is reduced, thereby converting it to a red-shifted analog with an excitation of 628 nm and emission of 638 nm. In addition, the fluorescent red-shifted reduced substrate becomes entrapped and accumulates within the live cells and can generate enough signals detectable by various fluorescent microscopes (Figure 1b) . The red-shifted signal separates it from inherent autofluorescence of the cells, thereby improving the signal-to-noise ratio in cellular imaging.
For these reasons, this agent is a promising imageable probe for in vitro and in vivo applications involving NTR-mediated GDEPT. In our study, the stable NTR-positive cells showed a high level of imageable signals by both fluorescent microscopy and FACS analysis. The fluorescent dye entrapment within the cell is very prominent over time and a steady accumulation can be observed every few minutes (Figure 2b ). This does not interfere with other cellular functions as we could monitor a process of cell division over time, simultaneously when dye reduction and accumulation within LS174T-NTR cells was taking place (Figure 2c) . In the present investigation, we applied this in vitro optical probe to image tumor cells in live animals by optical imaging methods.
Following in vitro validation of the stable cell lines, tumor xenografts bearing NTR gene were generated in nude mice. SKOV3-NTR was slow growing, but LS174T-NTR and 293T-NTR cells developed larger tumors. In this exploratory investigation, we studied different tumor cell lines (SKOV3, LS174-7 and 293T), optical imaging instruments (IVIS-100 Imaging System and eXplore Optix), and different routes of substrate injection (intravenous and intratumoral) for optimum data acquisition. Tail vein injection of the quenched CytoCy5S into SKOV3/SKOV3-NTR tumor-bearing animals exhibited signal from the tumor xenograft within 10 min. There was a steady time-dependent signal enhancement, possibly due to dye entrapment that plateaued after 120 min (Figure 4b ). Similar outcome was observed in LS174T tumor-bearing animals (Figure 3b ). The signal conversion was faster and stronger when CytoCy5S was administered Noninvasive optical imaging of NTR GDEPT system S Bhaumik et al intratumorally to 293T-NTR tumors (Figure 4a ). However, we could not compare the signal intensity between various studies, as the experimental study designs were very different. Cell line, injection routes and optical scanners are some of the obvious differences. In addition, there are difference in animal batches, clonal selections, transfection efficiency and levels of gene expression in different cells. It was interesting to note that unlike bioluminescent signals, 31 which tapered within 2 h, the signal in these NTR tumors often persisted overnight. Such unique capabilities can open up many new applications in the areas of gene imaging and cell tracking. We also observed that systemic or intratumoral delivery of the substrate was leading to significant nonspecific signals from the abdominal areas of animals. This nonspecific conversion of CytoCy5S is an interesting finding in this study. The NTR gene is derived from E. coli, a commensal bacteria normally found in the digestive tract of mouse and other mammals. In addition, there are several other reductase analogs or somewhat analogous to NTR that are expressed by several other microbes in the gut. We believe that the quenched CytoCy5S was reduced by the microbes present in the digestive tract, thereby causing the nonspecific optical signals observed in Figures 6a and d. Our theory is supported by the fact that we could suppress the abdominal signal by 15-fold when the multiplication of the abdominal microbial population was inhibited by antibiotic treatment for 48 h (Figures 6a-c) .
A significant potential application of NTR reporter gene could be in the area of cell trafficking in vivo. Since the fluorescent dye can accumulate and be retained within cells over extended periods of time, the cells expressing this reporter could be preloaded with dye before injection in vivo, and their homing could be tracked in live animals by noninvasive optical imaging. Each preloaded fluorescent cell, like tiny lightbulbs, could be tracked to observe its accumulation and retention in the target organs with limited nonspecific background signals that are usually observed following systemic injection of the substrate. In the context of stem cell therapy, not only can we monitor and track injected cells, but in cases of cell therapy failure, the rogue cells could be eliminated from the body by effective prodrug treatment with CB1954 via GDEPT. 32 The results from this study present a new and interesting reporter gene that has enormous potential to the imaging community. As NTR is a well-established therapeutic gene, it is now possible to monitor the therapeutic potential of this gene in live animals by noninvasive imaging.
MATERIALS AND METHODS
Chemicals, enzymes and reagents
Plasmid vector pcDNA 3.1(+), cell culture media, fetal bovine serum, antibiotics (streptomycin and penicillin) and Lipofectamine 2000 transfection reagent were purchased from Invitrogen (Carlsbad, CA, USA). Restriction and modification enzymes and T4-DNA ligase were purchased from New England Biolabs (Beverly, MA, USA). Triple-Master mix Taq-DNA polymerase for PCR amplification was purchased from Brinkmann Eppendorf (Hamburg, Germany). Bacterial culture media and plastic wares for cell culture were purchased from BD Diagnostic Systems (Sparks, MD, USA). The plasmid extraction kit, DNA gel extraction kit, genomic DNA extraction kit and Superfect transfection reagent were purchased from Qiagen (Valencia, CA, USA). CytoCy5S was supplied by GE Global Research (Piscataway, Niskayuna, NJ, USA).
Construction of E. coli NTR gene in a eukaryotic expression vector
The bacterial Nitroreductase gene (NTR2) was PCR amplified from the genomic DNA extracted from E. coli (K12) by using a forward primer designed with NheI restriction enzyme site (ctcgctagcatggatatcatttctgtcgcct) and a reverse primer with XhoI restriction enzyme site (tatctcgagttacacttcggttaaggtgat). The restriction enzyme digested product was cloned to a corresponding enzyme digested mammalian expression vector (pcDNA 3.1(+)). The vector expresses NTR gene by a constitutive cytomegalovirus promoter. The sequenceconfirmed clone (BankIt1396077 HQ379432) was used in further experiments.
Cell lines
Mammalian cancer cell lines of different origin were chosen for the study. Colorectal adenocarcinoma LS174T, ovarian carcinoma SKOV3 and human breast adenocarcinoma MCF7 were purchased from ATCC and maintained in culture conditions as recommended by the manufacturer. Human Embryonic Kidney cell line 293T was grown in Dulbecco's Modified Eagle's Medium supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin.
SKOV3, LS174T, 293T, MCF7 cells stably expressing NTR gene
Of the four cell lines used in this study, LS174T and SKOV3 were transfected with NTR1 reporter gene construct, and 293T and MCF7 were transfected with NTR2 (R107H) reporter gene to generate stable cell lines. For simplification, we will use the generic term NTR in the rest of the manuscript. Cells were plated (2Â10 6 ) in 60 mm Petri plates and allowed to attain 80% confluency. The cells were transfected with 1 mg of cytomegalovirus-NTR plasmid using Superfect or Lipofectamine reagents following the manufacturer's recommended protocol. The transfected cells were selected and maintained under selective media supplemented with G418 (NTR1) or puromycin (NTR2). The stably transfected cells were evaluated for the functionality of NTR enzyme by emitted fluorescent signal by incubating with CytoCy5S, a quenched substrate of NTR.
Preparation of CytoCy5S
The commercially available red-shifted substrate CytoCy5S ((GE Healthcare) with excitation 628 nm/emission 638 nm) was dissolved in dimethyl sulfoxide to prepare a stock solution of 2 mg ml -1 . The substrate was used for all in vitro and in vivo experiments by diluting either in phosphate-buffered saline or in cell culture medium.
Validating optical imaging of stable cell lines by InCell-1000 Analyzer and fluorescent microscope using CytoCy5S dye 293T-NTR, MCF7-NTR, LS174T-NTR and SKOV3-NTR stable cell lines along with their corresponding controls were plated in flat bottom 96-well plates and cultured overnight. CytoCy5S dye (100 ng ml -1 ) was added to each well. Fluorescent signal emission from SKOV3-NTR, 293T-NTR and MCF7-NTR cells were recorded using Eclipse TE2000-U (Nikon). The signal from LS174T-NTR cells was imaged under InCell-1000 Analyzer with Cy5 filter 620/700. Serial imaging of the same cells was recorded every 10 min from the same FOV (field of view) for 90 min. Real-time dye conversion from live 293T-NTR stable cells was further recorded by FACSCalibur cell analyzer (BD BioSciences), where cells were tested every 15 min following treatment with the same concentration of CytoCy5S.
Dynamic fluorescent microscopic imaging
Cellular conversion of quenched CytoCy5S into a fluorescent substrate by NTR enzyme was dynamically recorded using a time-lapsed IX81 Motorized inverted microscope (Olympus, Center Valley, PA, USA). 293T cells stably expressing NTR enzyme were plated in a 35-mm Petri dish with 27 mm glass base. Twentyfour hours later, the cells were imaged following addition of substrate CytoCy5S (100 ng ml -1 ). The images were continuously acquired once every 2 min for 4 h using Cy5 filter. During the entire imaging session, the cells were maintained at 37 1C in the presence of 5% CO 2 in a special weather-controlled chamber attached to the microscope. The image sequence was reconstructed and viewed for the events of time-dependent conversion of CytoCy5S in response to NTR enzyme within the cells.
Noninvasive imaging of SKOV3-NTR, LS174T-NTR and 293T-NTR tumor xenografts in live mice following administration of CytoCy5S
The Institute animal research committees at GE-GRC and Stanford approved all animal handling. All animals (CD1, nude mice) were purchased from Charles River Laboratories (Wilmington, MA, USA). Animals were imaged in two different optical scanners (1) eXplore Optix-Fluorescent Imaging system (ART Advanced Research Technologies Inc.) and (2) IVIS-100 Imaging System. In group (a), SKOV3/SKOV3-NTR cells and LS174T/LS174T-NTR cells (1Â10 6 ) were implanted in the left and right shoulder of nude mice (n¼3 each). Tumors were allowed to develop for 2 weeks until the tumor size attained 1-3 mm in diameter. Animals were anesthetized and injected with CytoCy5S (500 ng) via tail vein in 150 ml of phosphate-buffered saline, and imaged under eXplore Optix (ART). A whole body image of the mouse was obtained to detect signal from the tumor. SKOV3-bearing animals were re-imaged every 10 for 120 min.
In group (b), 293T/293T-NTR cells (1Â10 6 ) were implanted in the left and right flank of the nude mice (n¼4). After the development of tumors to a size of 1-3 mm in diameters, intratumoral injection of CytoCy5S (10 ng in 5 ml) was administered to the mice. Animals were scanned under IVIS-100 Imaging System (excitation 588 nm/emission 660 nm). Intense signal was detected within 5 min of injecting the substrate and the animals were monitored further at different time intervals for 16 h. At the completion of the scans, the tumors were excised and imaged ex vivo by the same system under similar conditions.
Signal detection from stable NTR cells pretreated with CytoCy5S in live mice using eXplore Optix SKOV3/SKOV3-NTR cells were cultured in T25 flasks until 70% confluence. Cells were incubated in 3 ml of fresh media containing CytoCy5S (500 ng ml -1 per flask) for 3 h at 37 1C. The cells were checked for the presence of fluorescent signals under inverted microscope Eclipse TE2000-U (Nikon), trypsinized, washed and counted. SKOV3/CytoCy5S and SKOV3-NTR/CytoCy5S cells (1Â10 6 ) were implanted on the left and right shoulder region of nude mouse (n¼2). A whole body scan of the animals were performed under eXplore Optix for the next 8 days to determine the sensitivity of the instrument and longevity of the persistent imaging signal emitted from the subcutaneous tumor site of nude mice.
Imaging NTR enzyme expressed by the gut microbial population in living animals
We observed nonspecific optical signal from the abdominal region of the rodents caused by gut microbial population expressing NTR gene. To minimize the background signal, the animals were pretreated with antibiotics (doxycycline: Clontech, Mountain View, CA, USA), for 48 h before imaging to reduce microbial population in the digestive tract. The animals were imaged pre-and post-treatment following intraperitoneal injection of 50 mg of CytoCy5S and scanned under IVIS-100 Imaging System. The animals were imaged after 48 h, and the levels of fluorescent signal were recorded.
